Close Menu

NEW YORK – Bio-Techne said on Thursday that its fiscal year 2021 first quarter revenues rose 11 percent year over year, driven in part by growth in its Diagnostics and Genomics segment.

For the three months ended Sept. 30, the firm reported revenues of $204.2 million compared to $183.2 million in Q1 2020, and beating analysts' average estimate of $185.0 million. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.